<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900027</url>
  </required_header>
  <id_info>
    <org_study_id>IONIs-ApoCIII-LRx</org_study_id>
    <nct_id>NCT02900027</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides</brief_title>
  <official_title>Placebo-Controlled, Dose-Escalation Study to Assess Safety, Tolerability, PK and PD of a GalNAc3 Conjugated Antisense Oligonucleotide Targeting ApoC-III, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      IONIS APOC-III-LRx given to healthy volunteer subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single and multiple doses of IONIS- APOC-III-LRx - (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>The safety and tolerability of IONIS- APOC-III-LRx will be assessed by determining the incidence, severity, and dose relationship of adverse effects and changes in the laboratory parameters by dose. Safety results in subjects dosed with IONIS APOC-III-LRx will be compared with those from subjects dosed with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma pharmacokinetics of single and multiple doses of IONIS- APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>The maximum area under the curve (AUC) of IONIS- APOC-III-LRx will be assessed following single and multiple- dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the urine pharmacokinetics of single and multiple doses of IONIS¬-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>The amount of IONIS-APOC-III-LRx excreted in urine at selected 24-hour intervals [Ae0-24h] will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma pharmacokinetics of single and multiple doses of IONIS- APOC-III-LRx</measure>
    <time_frame>Up to 183 Days</time_frame>
    <description>The maximum plasma concentration (Cmax) of IONIS- APOC-III-LRx will be assessed following single and multiple- dose SC administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma pharmacokinetics of single and multiple doses of IONIS- APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>The maximum time to Cmax (Tmax) of IONIS- APOC-III-LRx will be assessed following single and multiple-dose SC administration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with plasma apolipoprotein C-III (apoC-III) compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with TG compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with total cholesterol (TC) compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with low density lipoprotein cholesterol (LDL-C) compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with high density lipoprotein cholesterol (HDL-C) compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with non-high density lipoprotein cholesterol (non-HDL-C) compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory pharmacodynamic effects of IONIS-APOC-III-LRx</measure>
    <time_frame>Up to 183 days</time_frame>
    <description>Effects of IONIS-APOC-III-LRx on changes in levels of oxidized phospholipids associated with very low density lipoprotein cholesterol (VLDL-C) compared to baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Elevated Triglycerides (TG)</condition>
  <arm_group>
    <arm_group_label>IONIS-APOC-III-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APOC-III-L-Rx</intervention_name>
    <description>Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection</description>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator</description>
    <arm_group_label>IONIS-APOC-III-LRx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Healthy males or females aged 18-65 inclusive

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  BMI &lt; 35.0 kg/m2

          -  Subjects must have Fasting TG ≥ 90 mg/dL or ≥ 200 mg/dL depending on Cohort assignment

        Exclusion Criteria:

          -  Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             screening

          -  Regular excessive use of alcohol within 6 months of Screening

          -  Use of concomitant drugs unless authorized by the Sponsor Medical Monitor

          -  Smoking &gt; 10 cigarettes a day

          -  Considered unsuitable for inclusion by the Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Faulknor</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioPharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioPharma Services</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

